110351-91-2
Chemical Structure
(R)-Exatecan Intermediate 1
- CAS No.: 110351-91-2
- Formula:C13H13NO5
- Molecular Weight:263.25
IUPAC Name: (R)-4-ethyl-4-hydroxy-7,8-dihydro-1H-pyrano[3,4-f]indolizine-3,6,10(4H)-trione
InChIKey: IGKWOGMVAOYVSJ-CYBMUJFWSA-N
SMILES: O=C1[C@@](O)(CC)C(C=C23)=C(CO1)C(N3CCC2=O)=O
Biological Activity: (R)-Exatecan Intermediate 1 is a key intermediate in the synthesis of Camptothecin (HY-16560) derivatives, and can be used to prepare Exatecan mesylate (DX8951f) (HY-13631A). (R)-Exatecan Intermediate 1 enables the synthesis of Exatecan, which exhibits low sensitivity to multidrug resistance and has great value in anti-tumor research[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
(R)-Exatecan Intermediate 1 | (R)-Exatecan Intermediate 1 is a key intermediate in the synthesis of Camptothecin (HY-16560) derivatives, and can be used to prepare Exatecan mesylate (DX8951f) (HY-13631A). (R)-Exatecan Intermediate 1 enables the synthesis of Exatecan, which exhibits low sensitivity to multidrug resistance and has great value in anti-tumor research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 1.00
HY-42487A(rac)-Exatecan Intermediate 1 -
Similarity Score 1.00
HY-42487RExatecan Intermediate 1 (Standard) -
Similarity Score 0.78
HY-42487S1Exatecan Intermediate 1-d2 -
Similarity Score 0.74
HY-42487SExatecan Intermediate 1-d5 -
Similarity Score 0.65
HY-45171Exatecan intermediate 12 -
Similarity Score 0.56
HY-16560Camptothecin -
Similarity Score 0.56
HY-16560B(R)-Camptothecin -
Similarity Score 0.55
HY-N0095(S)-10-Hydroxycamptothecin -
Similarity Score 0.55
HY-N0275(±)-10-Hydroxycamptothecin -
Explore the MedChemAI to find more analogs
References
- [1]. Zhong MinLin, et al. Self-driven water collecting surface with superhydrophobic-superhydrophilic structure and preparation method therefor. WO2020000868A1.
- [2]. Weng W, et al. Antibody-Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer. Cancer Discov. 2023;13(4):950-973. [Content Brief]
- [3]. Conilh L, et al. Exatecan Antibody Drug Conjugates Based on a Hydrophilic Polysarcosine Drug-Linker Platform. Pharmaceuticals (Basel). 2021;14(3):247. Published 2021 Mar 9. [Content Brief]
